SecBot SecBot
PRESS-RELEASE ·Filed Apr 28, 2026

ORKA

Oruka Therapeutics, Inc.
BEARISH
Impact 6/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

Expect near-term selling pressure from the dilutive offering. Monitor the stock for potential support around the offering price. The company's cash position strengthens, reducing near-term financing risk.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$68.10
T+0 close · Apr 28, 2026 · via day close
Latest settled
+35.33%
T+60 · $92.16
Vs SPY
+31.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 29 $68.10entry
  2. T+1 · 7mo ago 0.00%α −1.02% · $68.10
  3. T+5 · 7mo ago +1.25%α −1.86% · $68.95
  4. T+20 · 6mo ago −14.85%α −20.31% · $57.99
  5. T+60 · 4mo ago +35.33%α +31.22% · $92.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oruka Therapeutics priced an upsized underwritten public offering of 9.66 million shares at $72.50 per share, raising approximately $700.4 million in gross proceeds. The substantial dilution (~18% of current shares outstanding) is likely to pressure the stock near term, though the capital bolsters its clinical-stage pipeline.

Key Financial Metrics

Deal Value
$700.4M

Key Facts

  • Offering of 9,660,000 shares at $72.50 per share
  • Gross proceeds of ~$700.4 million
  • Underwriters have 30-day option for additional 1,449,000 shares
  • Expected closing on April 30, 2026
  • Dilution of approximately 18.4% (21.1% including greenshoe)

Financial Impact

~$700.4M gross proceeds; dilution of ~18% of pre-offering shares outstanding

dilution

Risk Factors

  • Further dilution if underwriters exercise the greenshoe option
  • Stock overhang as new shares enter the market
  • Clinical-stage biotech with no approved products; execution risk remains

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3283352

Track record

40 reports on ORKA

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 10 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
  3. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
  4. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  6. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  7. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
  8. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  9. Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
Showing 10 of 40

US Market Status

Market Closed · Opens in 9h 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026